
The big number three.
"On September 21st, 2009 Neuralstem , Inc (www.neuralstem.com) announced FDA approval for a phase I trial of spinal cord derived stem cells as a therapeutic intervention for patients with ALS. Now that we have approval from the FDA, our proposal will be submitted to Emory’s Human Investigations Committee for approval. This process to ensure the safety for our patients will take several weeks or possibly months, and we will keep this site updated with our progress. At this time, we do not have a date when we plan to release details of the proposed trial, including selection of participants."
Neuralstem Press Release
"No mention of how long the treatment's effects carried on in the lab animals, if or when they relapsed...or of side-effects. Everything I've heard so far is that the results are only temporary, and the effects incomplete. Any news or links that would give us more details?"
"This is a 24 month trial. they will be treating 18 people maybe. If some die in the process they will probably halt the trial. Don't wan't to be negative, but it's just so invasive. they will open up the spine and give injections into the spinal cord."
"I was told at clinic that they would be forcing the needle into the spine and then pulling it back to make room for the cells that would then be injected. I'm not sure how much damage will be done by sticking the needle into the spine. Also they will be making several injections along the spine as the cells don't gravitate. Not being a scientist I don't know why this is so important other than we have ALS everywhere and it seems they believe it is necessary based on their findings in animals. I just wanted to post what was on the article that I recently read. Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and ALS. Neuralstem plans to initiate a Phase I clinical trial to treat ALS with its stem cells. hope this helps."
ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
Neuralstem is the first company to commence a stem cell trial to treat ALS. The trial will study the safety of Neuralstem's cells and the surgical procedures and devices required for multiple injections of Neuralstem's cells directly into the grey matter of the spinal cord. The FDA's approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year.
Neuralstem CEO and President, Richard Garr, stated, "The beginning of our clinical trial program is a major step towards achieving Neuralstem's goal of treating ALS, a fatal neurodegenerative disease for which currently there is no effective treatment or cure. While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process. This trial will be in the extremely capable hands of Dr. Eva L. Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery, and Dr. Jonathan Glass, Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, world-renowned for their study and treatment of ALS patients. We believe that there is no better team to conduct this study for us," said Garr. Their participation is subject to formal IRB approval by their institutions.
"We are very excited about this clinical trial," said Dr. Eva L. Feldman, who will direct the Neuralstem clinical trial program for ALS. "This is a major advancement in what still could be a long road to a new and improved treatment for ALS. ALS is a terrible disease that ultimately kills by paralysis," said Feldman, who also directs the A. Alfred Taubman Medical Research Institute. "In work with animals, these spinal cord stem cells both protected at-risk motor neurons and made connections to the neurons controlling muscles. We don't want to raise expectations unduly, but we believe these stem cells could produce similar results in patients with ALS," Dr. Feldman concluded.
About the Trial
The ALS patients will be treated through spinal injections of its patented human neural stem cells.
This first trial, which will primarily evaluate safety of the cells and the surgery procedure, will ultimately consist of 18 ALS patients with varying degrees of the disease. The FDA has approved the first stage of the trial, which consists of 12 patients who will receive five-to-ten stem cell injections in the lumbar area of the spinal cord. The patients will be examined at regular intervals post-surgery, with final review of the data to come about 24 months later.
Neuralstem expects to conduct the trial at Emory University with Dr. Jonathan Glass, M.D., Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, as site Principal Investigator (PI) and with Dr. Nicholas Boulis, M. D. performing the neurosurgery. The overall PI for the ALS trial program is Dr. Eva Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
About Neuralstem, Inc.
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem plans to initiate a Phase I clinical trial to treat ALS with its stem cells. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Pre-clinical work has shown Neuralstem's cells to extend the life of rats with ALS (as reported the journal TRANSPLANTATION, October 16, 2006, in collaboration with Johns Hopkins University researchers), and also reversed paralysis in rats with Ischemic Spastic Paraplegia, (as reported in NEUROSCIENCE, June 29, 2007, in collaboration with researchers at University of California San Diego).
Scientists Identify Genes Linked To Lou Gehrig's Disease
ScienceDaily (Sep. 9, 2009) - Michigan Technological University researchers have linked three genes to the most common type of amyotrophic lateral sclerosis (ALS), generally known as Lou Gehrig's disease.
Professor Shuanglin Zhang leads the team of mathematicians that isolated the genes from the many thousands scattered throughout human DNA. He notes that their discovery does not mean an end to ALS, but it could provide scientists with valuable clues as they search for a cure.
It can't come any too soon. Zhang started showing symptoms of the disease himself four years ago. He now breathes with support from a respirator and works at home with the aid of a research assistant and his wife, Qiuying Sha, an assistant professor and member of his research team.
"I felt very urgent to find the genes for ALS," he says.
"This is very nice work," said Xiaofeng Zhu, an associate professor of epidemiology at Case Western Reserve University's School of Medicine. "It's very challenging to map genes for complex diseases, and while many statistical methods have been developed, most don't work well in practice. Zhang's group has developed a method to detect genes and gene-gene interaction in complex diseases and provided evidence that it works.
"Their findings will need to be confirmed by other researchers, but I think this will be very useful for the investigators who are trying to find genes underlying complex diseases such as ALS," said Zhu.
According to the ALS Association, only about 10 percent of patients have familial ALS, a directly inherited form of the usually fatal neuromuscular disorder. The remaining 90 percent, including Zhang, are diagnosed with the sporadic form of the disease. While scientists have long suspected that genetics plays a role in sporadic ALS, they have had no evidence to back it up, at least until now.
Everyone has the three genes in question. But in people with sporadic ALS, they differ from those in people who don't have ALS.
The mathematicians were not surprised when they tracked down the genes' street address. "Everybody has 23 chromosomes, and the three genes on chromosomes 2, 4, and 10 interact," explained Sha. "If you have this combination of the three genes, you are at high risk of developing the disease."
"It's really exciting, especially because my husband has sporadic ALS," she adds. "Maybe they can find a cure by blocking the genes."
According to the ALS Association, approximately 30,000 Americans have ALS, and about 5,600 new cases are diagnosed every year. The disease destroys the nerves in the brain and spinal cord that control voluntary movement, eventually leading to paralysis.
Zhang's team used a new statistical method to analyze the genetic codes of 547 individuals, 276 with sporadic ALS and 271 without. Their method, a two-locus interaction analysis approach, allows the researchers to identify multiple genes associated with a complex illness.
The data set they analyzed was provided by National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center at the Coriell Institute, a publicly funded "bank" or repository for human cells, DNA samples, clinical data, and other information that aims to accelerate research on the genetics of nervous system disorders.
"Ideally, we should confirm our results in a second data set, but we don't have one available," Sha says.
ALS is not the first condition they have tackled. Using data sets provided by University of Cambridge, Zhang, Sha and their colleagues have also identified 11 genes linked to type 2 diabetes, which has reached epidemic proportions in the U.S.
The team hopes to apply their methods to other medical conditions, but has been hampered by the lack of genetic information: most data sets are not freely available to researchers. Zhang found out about the ALS data sets serendipitously, while searching the ALS Association website for information on his condition.
"Unfortunately, we don't have access to more data sets," said Sha. "If we did, we could analyze even more diseases."
Their work is being funded by a grant from the National Institutes of Health. In addition to Zhang and Sha, the other coauthors are Zhaogong Zhang from Michigan Tech and Jennifer Schymick and Bryan Traynor of the National Institutes of Health.
Journal reference:
1. Shuanglin Zhang et al. Genome-wide Association Reveals Three SNPs Associated with Sporadic Amyotrophic Lateral Sclerosis through a Two-locus Analysis. BMC Medical Genetics, (in press)
Adapted from materials provided by Michigan Technological University.
by Frank Deford
September 2, 2009
Muhammad Ali flew to England last week, there to make appearances in soccer stadiums. He said it would probably be his "last time" in the U.K. He can barely move on his own now.
One London newspaper called Ali, who was once "a butterfly," "little more than a zombie." And a great many people find it as upsetting as it is sad that the old champ continues to make personal appearances.
Maybe it would've been best if our last image of him had been in '96, when he suddenly appeared out of nowhere and — already shaking terribly from Parkinson's — still managed to light the Olympic flame. There was a nobility to that scene, as if once more he'd gotten off the canvas, managed somehow to win another fight.
But Ali wouldn't retire from the ring when he should have, and now he refuses to comfort us and slip away from public view.
Perhaps there's a bolder statement in that, that the man who once so immodestly enjoyed standing before us — the laird of his realm, proclaiming his beauty to the heavens — is now unafraid to let us see him when his great body is slumped, in shambles.
We want to remember the paragon, not the mere human.
But might we be too tender with our memories? The athlete dying young has always seemed so shocking, so unfair — but I suspect that it upsets us even more to actually see our heroes, those physical marvels, grown old and infirm, as vulnerable to age and disease as we ordinary folk are. We want to remember the paragon, not the mere human.
Ah, but in contradiction, Ali's wife, Lonnie, speaks for her husband, saying that for as long as he can manage to travel and make silent appearances, it "is not just his living; it is his life." There must, for him, be as much in satisfaction as in remuneration that he can still command up to $100,000 just for showing up.
The busted old pug was long a stereotype in our athletic cavalcade. That Ali is broken — but not broke — is a certain revenge. And he, who was once so reviled by so many Americans, has become quite a beloved figure in his dotage. Complicated as he has been, he won the fight for our affection, too.
I can so vividly remember, a few years ago, when a photographer posed him before the Vietnam Veterans Memorial in Washington, D.C. I thought that was insane. Who, after all, was more identified with opposition to that war?
But when the people there — searching for the names of their loved ones who had died for what Ali opposed — when they spotted him, they rushed to him, even handed me their little cameras to take snapshots with him, embraced him. It was dear.
Even as boxing, as a sport, fades to the fringes, Muhammad Ali still retains some kind of hold on us. If he yet wants to present his present, lesser self to us, it is not for us to feel pity for him.